HHP
Control death day
Remaining ratio
Drug
MRD
RUmax
pA2/pKB
Time in light
Cytotoxic concentration
Clearance_blood
increase in response
No. of depolarizations
s-GPT level
Jss
Mean latency
ED75
Control of growth
Remission
Log II50
Relative rate metabolism
Cation influx
Relative molar potency
CPM
beta t1/2
Remaining activity
Vaginal activity
Drug level
kp
logP
Safety ratio
Eosinophils
Decrease in arterial blood pressure
BsI
SSAT
Inhibitory dose
Anticonvulsant activity
Mean graph mid point
Plasma insulin
Gastric damage
Average body weight change
Fold change
Gastric concentration
Urine output
No. of mice surviving >6 months
UI
Changes in airway resistance
Binding ratio
Fh
Decrease in RFU
Transporter production rate (r)
MGDH GI50
LH concentration
Lesion frequency
C5a affinity
Apparent binding constant
kinact/Ki
SDL
Max plasma level
Cmax/SS
LD90
Delta ERP
Onset of block
Max platelet response
HVA level
Urinary Na+
MED100
Ring immobility
kA-
T/C (tumor vol)
Lowering activity
Weight loss
Delta TG
Pyrogenic effect
No. of falls
SC50
No. of rabbits convulsed
PTZ protection
GT fold stimulation
T/C @ 30mg/kg
Unwinding
PR
Ratio pKb
LD50
FBP mean score
Log change
Partition ratio
Ki comp
Mean volume of hind paws
NCC
Log k'w
Fluoroscence
Ca2+
Intensity of erythemia
AUC 100
GSH level
Rlung
Skin thickness
increase in mean survival time
Toxic
Exploration motility
pKinc
VAR
Max vasoconstriction
Mean effect
Max increase
log Ks
VV
Maximal non-toxic dose 50
K obs / 1 1/Ms
Control Uptake
Resistance
BWC
Agonism
Clonic
Animal death
Insulin secretion
Decreace in BP
Inhibition concentration
Injected dose (g)
Mean day survival
C/P
ICL5
Plasma MIC
Thermogenesis
Edema variation
NBT reduction
Change in cholesterol
MID log LC50
Chelator
Reduction in prostate weight
T/C 1.2
Hill coefficient (n50)
GMS activity
Total cells
Cyotoxicity
Inhibition type
Competition
Egg reduction
GC200 [d]
Accumulation
MDD50
SLI
RMP
Mass index
Increase in LD50
Tumors
No. of emetic episodes
I 90
Cytotoxic endpoint
Brain
TPO(max)
kOH
logEC50
Acid titer
Change in amplitude response
Sublethal dose
Relative analgesic potency
DT
No. of animals survived
Dose/g tissue
Frel
Delyse
Weight change
ED25
Antimalarial activity
Vasodilatory rate
Rectal temperature
Responding
Loss of righting reflex
No. of writhes
No. of new tumors
Change in BP
Observed at
Walking behaviour
Kinact
Na+ output
Relative
Anti-Factor Xa activity
Relative ionotropic activity
Effectiveness
Max APD95
KNa
TTO
Inhibition at 10nM
Percent remaining
QT interval
Peak concentration
Ke naloxone
Change in volume
Reverse potential
Log koff
Arthritis scores
Ratio CC50/EC50
Uptake rate
Aspirin formed
Ks app
ILC
Relative antiandrogenic activity
No. of toxic deaths
Analgesicactivity
1-logKi
Vehicle control
AUC total
Fluorescence activity ratio
Decreased_triglyceride
AP
kC,U
Concentration in Brain
Twitch tension
Deuterium retention
Mean aortic blood pressure
ClC95
Delta Tm
Max suppression
Maximal effect
Aqueous solubility
Derived trabecular thickness
Thylpositive cells
Kd
Cr
p value
Average survival
K obs
Cooperative effect
Ratio Ke
NADH content
Inhibition uptake
CQ
Uterine weight effect
X1(50)
Antifertility activity
Occlusions
Highest nontoxic dose
I14
Dopamine release
Radioactive absorption
Serum metabolite
Tm shift degreeC
H2O2 prot
rb
kIAM'
dpm bound to protein
No. of suncus vomited
Vagal response
Hepatic triglyceride
MLC50
Ratio plasma concentration/IC50
Maximal binding
KdSPR
AUC inf
Catalepsy
Anesthetic effect
Gellar cook activity
I50 M
[I] for Km'
Onset seizure
Conversion dose
Tumor free survivors
MCC50
Normal
Area
Decrease in MAP
HDT
Antiinflammatory Activity
Cat score
Cells sickled
Homovanillic acid concentration
Change in systolic pressure
MFC
PC50
Brain penetration index
Log (1/C)
Skin tests intensity
Irritation of eyes
B
Counts
Activity Score
ICmax
CLd
%Remaining
K13+K23
Cp(f)
HR/chol
Average weekly weight change
Progressed remission
No. of virus free mice
DBP/UP ratio
Cells killed
pD
Protein
Relative intensity
EC1000
Rmax
No. of escape failures
Log relative k'
Cataleptic effect
Log k GSH (s-1)
Ultrafiltration
LCK
% absorbed
Rhodamine-123 accumulation
deltaTm
T4
cell kill activity
No. of males fertile
No. of males cohabited
VF
Specific incorporation
Duration of anesthesia
Killed
Concentration in serum
Control cell number
E1/2
Weight change difference
log(1/IC50)
Histone_modification
Serum LDL-cholesterol
pMIC
GABA current
Unbound plasma
Chlorine uptake
Ratio Ki
Anti-analgesic
pKm
P50e
Lipid-soluble radioactivity
logPm
No. of openarm entries
Currents
Degranulating activity
IT50
SubG0
Count/h
Serum TG
Increase over control
pIC50
ERP
Control
Relative affinity
logKw
Last therapy day
Solubility
t1/2
logRA
Duration of action
Positive cells
IG
MI100
Cmax_ratio
Tc
Photoxic reaction
Permeability index
Ti
t
Apoptosis induction
Mean time to death
LD95
pKa BN
Food intake
ALP Level
KT
T-cell inhibition
p[A50]
Delta mean blood pressure
TRAP staining
CC100
EC16
Ca2+ flux
IC50/IC50
TEWL
LV
Decrease in mean arterial pressure
pC30
Nephrotoxicity
MfI
Convulsion
Ca2+ antagonism
PFU/ml
LWI
Actual clearance
Fold_activity
Log rate constant
Coronary flow
Dead cells
Max.stimulation
logPc
MTA
T3/4
logS0
Dissociation
Tumor growth delay
AbA/analogue ratio
Delta Gsolv
-Log alpha
K cat/Km
VR
Injected dose/g tissue
Kii
Control at the dose of 50.0microg/mouse
Rotarod toxicity
Binding Decrease
Broncho selectivity
Rate of [Ca+2] increase
Total peripheral resistance
ks
Median tumor
cpm
Acute lethal toxicity
Uptake ratio
Abrasion score
Attacks
Reversal ability
lnK
Slope of Schild plot
R.I
IC27
MTC
Contractility (LV dP/dt)
Protein interaction energy
logGI50
Adrenal uptake
Pressure
Naproxen produced
logC50
Substrate activity
Epoxide formation
Kid
C 8 h
Log Pc18
Mean total resorption
Difference
p[BH+50]
Cartilage space
Potential
Stereotypy score
Enoyl-CoA hydratase
MTT reduction
Log AP
Decay-time constant
I
MTT
pTGI
Arterial pressure
Max blood pressure fall
Alpha 50
Worm reduction
Log 1/C
VCT
CT3
Neurite bearing cells/total cells
CMpH
ED50 Ratio
Loss of inactivation
Relative inotropic potency
Decrease in AP
Mean IC50
MED
Log Poct Z
Glyceamia evolution
No. of males mated
Cell viability
No. of mice alive
Changes in dynamic compliance
Dose (urinary recovery)
No. of rats ovulated
Relative JC-1 accumulation
Mean total plasma concentration
LV dP/dt
C/I ratio
Photolysis
Mycelial growth
DAR
T/C
K1/2
T inh
RBP
-Log ED50
Log 1/Km
Antihypertensive
Differential
Log 1/E100
p nMED
FIC
EDmax
Incidence of occlusion
Change of DBP
Inhibition
Log IC50(uM)
MPC
Concentration of max response
Plasma triglyceride
HMGR activity
Infectious virus
Reversible
n50e
Brain content
Femoral blood flow
Paraparetic mice
Relative inhibitory activity
Relative intrinsic activity
Cross reaction
I50
Acid output
DNA crosslinking
Increase in plasma lipase
ID40
Basis motility
Inhibition effect
K+ output
AC
log10cfu
Actual duraction
pC1
Vmax / K
CLm
Relative contractile potency
MTD/8
Change in dP/dt
V/K
t0.9
Fold selective
AA
HCMV yield
MED99.9
ED 50
Inhibition potency T/II
k_2
KI50
Brain concentration
Formation
tox/total
Preventive_index
Systolic blood pressure
IC50 reduction
30 days survivors
HAR
Delta APD90
Mean day of death
Colony formation
RPF
RH
Hypotension
Occ ED50
Survival increase
MFC50
Molar potency
Predrug
SMT
Temperature decrease
Uterotrophic activity
Tumor burden
IC80
T-cell
Tensile strength
T-C/C
Rate acceleration
MST
Ratio_EC50
cAMP production
Average dose
Binding
Counts of rotation
PKa2
AD100
Nr/N
Increased life span
Maximum inhibition
ascrit
Injected dose
PActivity
P50d/P50c
Saluretic potency
Marrow area
Delta pKi
Bound
Log 1/MIC (mM L-1)
Anticoagulant activity
Recovery
CIC
DW
SGOT activity
Total coenzyme
LED100
LogD5.0
Counts/30
No. of infected cells
Spontaneous reperfusion
Total rate
Curative Index
Rs
Competitive protection
Permeability coefficient
ICdATP-50
ILSmax
lesions
MTL
Range of survival days
Min plague Inhibitory
Ratio EC50
Heart rate
Dead/treated
PA
TCT
Survivors / treated
T/C min
T decrease
Max decrease in heart rate
Vm rel
LV dP/dTmax(delta)
Iron mobilization
Basal glucose
Least dose
PDH active/PDH total
Antagonism effects
pK2
K aps
Reserpine hypothermia
Venom
Ki high
Post anitbiotic effect
Affinity constant
Delta F
Specific radioactivity
Rate of inhibition
Basal activity
CLT50
IW
Prolongation
PD2
Staining potential
KSV
Cr leakage
Diameter of inhibition zone
E2 response
Delta F75
Oral diuretic activity
FLT
Log10ED50
HD50
KB app
Cmin_ratio
KF
TI
Spontaneous activity
ED37
FBP
Synergy
Eicosanoid production
Log P/(100-P)
Cmax_metabolite
Substrate efficiency
Approximate colony formation unit
Thymidine reversal
Oxygen consumed
pinhibition
No. of mice protected/tested
Total counts
Cross linking
PKC
Cells positive
Ki slope
EC150
Drug concentration
NAD+ content
T/C @ 50mg/kg
cAMP accumulation
Rate constant
Ca2+ binding protein
cAMP
Respiratory system resistance
ka/kr
Average survived
Ac50
LD60
EC5
Time to max. inhibition
Electrolyte excretion
ITI activity
Kkin
Rate
-Log EC20
GTPshift
Stroke volume
DHP-I susceptibility
Ki'
Normal weight gain
Binding activity
TP
Binding intensity
Max inhibition concentration
Log A50
IC35
BBR
n
RD1000
EC80
Prodrug remains
krel
CBF increasing activity
LD99
Inotropic potency
Decrease in CR
Basal uptake
Glucose transport
Postsynaptic antagonist
B incorporation
Max APD90 (delta)
Average for skin reaction
Duration of peak action
Maximal change
Alpha-cholesterol
Uterotonic activity
Growth Index
Bathochromic shift
DL50
Peak time
DPM
Animals cured
Range
LogK-IAMex
KA effect
TPI
F_fraction
Vasoconstriction effect
Acc. counts
Hexobarb ST
RHA
Relative toxicity
TOX
Difference in retention time
Spont activity
DNA unwinding concentration
No. of WDS/60 min
Basal
B/P
Max efficacy
Lesion
Elevation
Partition coefficient
Total dose
Weight change at nadir
GM-MIC
Kr/kmax
Decrease in IC50
nNOS activity
Log Kmemb
Max lowering
Selectivity index
Inflamed
ALT/GPT
k_off
Hypnosis potentiation
Ventricular rate
koff
Parasites no. per 100 Myoblasts
LD40
EC14
Tremorolytic dose
Skin response
Rate of decrease
Tumor weight reduction
Weight (mg/g)
Triglyceride level
AUC nom
Max relaxation
Osmolality
GDP activity
LDL
ke
No. of animals
S.I
Intraperitonal score
RD50
Relative Km
Primary tumor weight
Basal binding
mBP(delta)
Body weight gain
Behavior
Phosphorolysis
k x10e-3
No. of pits
EC2x
Aggregates
Average food intake
Increase in [Ca+2]
Survivor increase
Analgesia
Mouse behavior activity
CAI activity
Cellular reversion
Isometric contraction
No. survived
Selectivity Index
Intestinal toxicity
T.P.L
Kapp
Potentiation
I30
Virus yield
D/P
ED58
PC100
Activity
Log A
Cellular uptake
Ventricular MAPD90
UR
Kic
T
Phospholipidosis_index
Volume change
Antihypertensive score
Vascular relaxation
Log10CCID50/g
Stability of BSR
Functional selectivity
Formation of NO3-
PMA
Amount formed
Serum TSH
ABD50
PFC/spleen
AUC glu reduction
2xAPTT
TCI
Amine formed
T/C @ 40mg/kg
Sleep ratio
Reduction in virus yield
No. of animals protected/number of animals tested
Volume of air
Saluretic activity
ODC
AC3
BP
Implants
CA
T/C x100
Range of MIC
P/D
Kkmax
Max binding
GSH reactivity
Plasma ALT at 24 h
Anticonvulsant
pK3'
Spermidine concentration
BAV
Antilipid peroxidation
Change of CO
Vertebral blood flow
Renal clearance
Ulcer Index
ALT
pKL
No. of avoidance
Cures@ 40 mg/kg
MI50
ODC Activity
Mean no. of shocks
Trans
SOD activity
ICL50
IC100
Concentration ratio
delta logPoct-dod
Epidermal thickness
Change in foot-licking latency
Mean AUC
Max drop
Fapp
Active dose range
Protein-DNA complex formation
ASF
logIC50
Decrease in blood pressure
Thromboxane B2 (TxB2)
Controls
Mean change
30 day survival / total
Brain/Blood concentration
No. of animals exhibiting toxicity / Number of animals tested
Varea
Log 1/MIC
Anti-pent effect
permeability
Mean activity
LV dP/dtmax
Molar ratio
Collateral index
Gain
DFM
Compound remaining
Time over 100ng/ml
Platelet aggregation
Cures@ 80 mg/kg
PSA
Paw swelling
RRT
I7
B/P ratio
Decrease in exit latency
Dec
RD500
Cr release
Psychotropic Effect
KD2
EIR
Apoptosis
CLogD7.4
Hydroxyproline release
pKi(uM)
Average survival days
No. of lung metastasis
Abdominal fat
log(1/CON)
ND
k act
Deaths
keq
Anti-uterotrophic effect
Paw weight
Ba
Log d50
k/K
Log RAI
pC25
LD50 x 1/40
Cholesterol
Kieq
Log Po
Ratio I/P
Beats/min
MNTD
g/30min
Protected/Tested
Log 1/Kd
Carnitine acetyl transferase
Log Ki
Cell saturation
TC25
Allodynia score
Plasma TC
No. of tumours
No. of strains
MyristoylCoA
Weight change of AP-S
No. of nonpregnant/treated
Vasodilation
Intake
MNEC
Log 1/B+1
R
GTP-gamma35S bound
TED
Cumulative amount
Succeeded/tested
GABA shift
MBC90
Log 1/Th+200
ED85
t1/2_ratio
GSTCP activity
SNGFR
EC0.25
1/krel
PAO activity
T1/2 iv
Ratio ki
N/A
Gastric lesion score
Log K3
RPP
TGI ratio
Regiospecificity
Serum level
No. of animals protected / no animals tested
Cutaneous toxicology score
Bioreduction
Cured
rate constant app
Test/control survival
Amount excreted
Responder
tR
Total tumors
log10EID50/g
No. of cells
Ko
Glucose lowering relative to positive control
kH
MFC90
Active/total cultures
Cell no./dish x10E5
Change in sensitivity
Average gross pathology scores+/- SE
PF50
IC99
RBI
RBF
MRTV
Log activity
Clearance
Peak deltaMAP
Day of first positve reaction
Log KH
PI metabolism
ln Kt
k2c
Agonistic effect
T/C value
Tlag
XC50
Postjunctional agonist potency
Delta mean survival time
Tmax
Activation Factor
Tm shift
Rn
Change in stroke volume
reduction in CL_renal
ET-1 level
Tail flick latency
KdSPA
Delta p
ID/g tissue
PDE inhibition
New tumors
Survivors at day 4
IC75
Antiproliferative effect
Ki.c
Mitotic figures
Change in TC
Plasma TG
Reaction time
Liver catalase
Passivity
Toxic/total
Convulsions
IFN gamma concentration
Vrel
pCF
TIME
ED delta20
MTD/4
LogP
External nucleoside
MRTinf
ALD50
No. of writhings
Relative inhibitory potency
Log K'
log(1/ID50)
Relative adrenal weight
Plasma
Log K4
Parasitemia
Log 1/T
RBC x 10e 3
No effective/ no. tested
Max change in blood pressure
Kup
Log sensitivity
Change in IOP
T/C (ratio of treated to control)
Unchanged tracer
Uterotrophic effect
E max
Log of inhibitory zone
influx_CL
log(10'6/IC50)
Baseline systolic BP
Damage score
IC90
Positive control
Clerance
Emesis
Macrophage cytotoxicity
Kact
Anti-fXa activity
Tonic-clonic seizure
Phosphor
Log [-6]
max inhibition
KHOX
Relative amount
Antibacterial activity
Uptake
Blood AcH
Fos
Inhibition Zone
Relative salidiuretic activity
Paw weight increase
EC25
solubility
CR
Thrombin time
[3H] TdR uptake
pD2
Unmetabolized
Relaxation
pKa2
N20 formed
E 1/2
k2 / Ki
Static remission
KD1
OSAV
Caco-2 A-B
Necrosis response
LC50 ratio
AMPA effect
DOM
Liver cholesterol
Max contractile force
k'
SBP
Punishment test msad
tCmax
E100
Mean relative potency
K inact/Ki
Vomits
Antidiuretic
DBP15
CT2
Relative influx
Potency ratio
QTc interval
KD/Ki
Antagonist effect
Lw/Bw
ID/g
Urea Nitrogen Concentration
Bleeding time
Hydrolysis rate constant
MIC70
Equilibrium OD340
Mortality range
Propioaldehyde generated
MTX ratio
Oxygen uptake
BW loss
Increases
pKd
Mice with lesions
Fungicidal concentration
FC
Log k'
C8h
A
EC99
Log 1/D40
[EOP']infinity/[EOH]infinity
No. of occlusions
Hypokinesia
Reflex
Log B/F
Time constant
Log Kobs
Kill at C50
Modification of hemoglobin
g/mouse
Log K' IAM
Pm
GT rate
GABA agonism
Damaged area
RP
BAT weight
No. of tumors
PPM
Dose modification
Change of CF
EC40
Decrease in QA interval
Bilurubin Level
Slow binding
Rate of recovery
K inact/I
[A]T,L
Mean paw diameter
Max potentiation
2*APTT
Latency to exit
Ki_app
APD
pEMR
Increase in concentration
IC70
Rate of turbidity change
-log(1/MIC)
Total release
Transport inhibition
Log C
Apoptotic index
Average survival (days)
NSR
Margin before onset of hypokalemia
CL
Log Poct N
Fibers/preparations
Na+ inactivation
No. of scratches
Sensitized animals
Volume reduction
Median survival time
Day of death
Initial mean arterial pressure
PCA shift
Critical micelle concentration
Transactivation
NAD content
LLR msad
Polyamine pools
Dead
efflux_CL
MPC8
Si
Activation time
Max hemorrhage
ID x kg of body weight/g of tissue
Log beta
Relative Ki
Edema density
% turnover
Phosphorylating activity
Fresh weight
Antagonist
ClB
LDL-C
Urinary volume
Pa
No. resp animals / Total
-Log KB
Survival after 30 days
Protection
Cures/no. of animals
%Cleared
Cocaine
SBP change
Antiovulatory activity
Relative initial rate
K app
Total score
Diuretic activity
Cell cycle fraction
Mean HR
pAI50
Cell survived
Function
Emesis_ED
CI50
Decrease of spontaneous firing rate
Decrease in SBP
LS
Natriuretic activity
Inhibitor level
Emax,diss
Mu/delta ratio
TG 2X lag
kR
No. of chicks
DIZ
Serum LH level
Intact
Anxiolytic activity
INCC50
CHI
Quench
GC50
Vd area
Weight at term
Rate max
Inotropic effect
Prejunctional antagonist potency
p[A]50
fp
Alpha max
Effective concentration
Anogenital distance
FA
Log Pmw
Log Pcyc
Cell permeation
Max protection
ZImax/KZI
Antagonism
IPA
Extent of skin lesions
[Ca2+] increase
Tumor free/total
Creatinine
TAR
%AUC
Apparent enzyme activity
Average lung weight
Total uptake
Immunosupressive activity
Plasma histamine
C20 APD95
Kd'
Effect
Du
Cmax_triphosphate
Peff
pIC50(calc)
Acetylation
Receptor occupied
Max uterotonic response
Entry latency
No. of transfers
ADI
Spent time
Incorporation rate
TWI
Blood flow
Cytotoxic effect
Photo-cross-linking of DNA
Cellular uptake of boron at 16h
Aggregation response
MABP change
LTC
Motility
Pharmacokinetic
max activation
GPI
fCmax
BUN
Survival rate
Log 1/M
Enzyme level
pKHB
Log 1/K
CT
Gastric emptying
Ts
AUC second treatment
Weight changes
Probability
No. of deaths
Tumor latency
Saq
Ratio IC50/EC50
&#256;
K m
LSD
Weight reduction
Cdyn
SC
ED2sec
Time constant T2
Time of dosing before antigen challenge.
TFS
LVP
Increase
delta pKa
log(10^6/IC50)
logt1/2
Zone size
Trabecular thickness
pK3
Reduction in respiratoryvolume
QT
Delta K
Reduction in blood pressure
NSVT
Plaque inhibition result
Hormonal activity
pC60
EC15
Antibiotic activity
Rm
CLtotal
EC90/MIC
Fold increase
Log
Hk
EC10
Chemotherapeutic index
Ratio IC50
pLD50
Iron excretion
Drug Conc (serum)
Max contraction
Log SOSIP
Glucose level
Plasma Level
Behavioral effect
CGI
Relative initial slope
Log TGI
Log 1/MEC
Specific activity
I.D./g
K app ratio
Tumor half growth
Cells in metaphase
Mean vesicle score
Log BR
Average score
Change in No. of trophozoites x 10E-5
Ratio GI50/EC50
pC2A
Metabolic stability
No. of culturesactive/total
No. of revertants per plate
Kn
Relative ID50
Mutation frequency
Change of SBP
C0
Accumulated counts/30 min
Agonist
NSR survival rate
DOPA accumulation
FD
Delta BP
2x PT
IC25
Change in FVR
RVCF
Polyamine level
NS
Rate of metabolism
Revertant colonies per plate
Adrenochrome formation
EBD20
Animals
Inhibitory potential
SHR delta blood pressure
LC90
Prejunctional agonist potency
K obs / 1
Blood glucose level
Pupil size
C70
MBP
Recovered radioactivity
kmax
Tumor uptake
FI
Ca2+ transport
-Log KD
UC50
LD5
Cell death
[A]
Intrinsic actvity
No change
Q50
KL
K2
tz
Progesterone production
ED35
pKD
Inhibitory diameter
logPF
Infarct
Blood glucose
Surviving factor
ID100
Inflection point
Dose converted
Differential affinity
pKH
Ratio_[3H]:tubulin
Log K delta
Fraction ionised
No. of positive cases
Inhibition at 1uM
Increase in CBF
[I] 0.5
Nitrate
Agonistic potency
No. of rats died
Reversion
LC50
EPMR
Average max
Phosphorylation
M/NTT
LMA
Log APA
Ca2+ elevation
Grip strength
Administered dose
Delta pH
TBPS IC50
AD
Sp St
MPO release
fAUC
Ulcer score
AR
Rate of oxidation
Relative enzyme activity
Zone of inhibition
N/D
FBA
Induced frequency
CC25
selectivity
GABA ratio
Kon
Glycaemia evolution
Cytotoxiciy
Change in Tm
MSD
Reversal type
Toxic dose
Relative efficacy
Mean hemagglutination titers
Haptoglobin
Initial rate ratio
Carbohydrate
IC50/EC50
T1/2 h
pLADm
Drug release
Feed consumption
P Increase
Cholesterol level
Acquisition time
Log tumor cell kill
Tissue levels
MHPG_SO4
BFU
HI
Relative inactivation
Ion enhancement
T1/2 h/s
cKi
K
Dose range
Suppression
Parasites
Average turns
Cortex_Clearance
Spreading
RW
IogP
Delta G
k eff (rel)
C6h
Lethal dose
Inhibition ratio
Relative daunomycin accumulation
Ki''
BHIA50
CIC IC50
FL-1
P-value
T1/2 increase
ECS ratio
Cp(T)
No. of animals with damage
Ki0
Turnover
Dosage
VFT
k+2/k
logD IAM
TR
CIC95
pTCD50
Urinary output
Of control
K50
Beta2 duration
Degrees Centigrade
Inactivation time
Control period
Of non-HDL-C
Testes weight
DBP-20
graft survival
Na+/K+
Depression
ACR
MI
Graft survival
Chronic TI
MLC
Max salt tolerance
CCCT
RFU
logPapp
Increase in footpad thickness
ED20
Max possible effect
Challenge time
ID (per g of organ)
Delta RM
Cooperativity
GR
KH
P50e / P50c
AOA
k3
Change systolic BP
Resorbing implants
Phospholipidosis_MEC
Log LD50
-Log KA
No. of active/no. of tested
Mean tumor delay
Vdss
Fluorescence intensity
Degree of activation
Insulin lowering effect
Average body weight
dP/dt max
Pigmentation capacity
Secondary response
Aggregation ratio
Heart beat
Drug uptake
Tissue concentration
Respiratory frequency
Change MAP
Thrombus weight
OMNI med
kHO
Drug Conc (LDL)
DP
pKapy
SBP decrease
CPmax
Resting potential
Cured/treated
Stenosis
FB
NO formation
TGI
av
k cat/Kuncat
SHR
Log Y
PAR
FPGS activity
pEC5
Mydriasis
Tumor cure
TDI
Log Poct A
Delta LV
Delta I
IZ/AAR / AAR/LV
Apoptotic cells
Unaltered compound
Infection score mean
Change of hemoconcentration
Performance
GOT Level
Increase in volume
Animals protected
P50e/P50c
ED99.9
Accumulated counts
T max
Untreated control
Iron binding
Sedative dose
Reversibility ratio
Uterine activity
No. of dogs reverted
Delta pEC50
Delta heart rate
AUC p
Tonic
Tidal volume
pKi1-pKi2
Total acid output
pH dependence
RTP
Partial remission
Fraction cleared renally
7-day weight change
Maximal efficacy
Reverse transcriptase activity
Relative viability
k eff
Caverage
kOX
Control at the dose of 5.0microg/mouse
Hypochromic shift
Anxiolytic affect
LRR
WEIGHT
SF50
Brain uptake
VT50
Plasma conc
Relative agonistic activity
Residual_activity
Antagonist efficacy
CMI
dP/dt
Growth inhibiton
Biological evaluation
ILSmaxOD
Concentration
Transfection efficiency
Vasopressor responses
Zinc finger reactivity
Antinociception
K rel
Empty
HSF
RVmax
PFA
Tumor
Weight difference
Log S
ST/CB ratio
Ratio LD50/IC50
Log Pe
Thymidine shift
IF
Free C
Synergy EC50
Extracted
Log LC50
SNA
washout
Protection ratio
Exhal+B1718ation of 14CO2
Cell aggregates
Severity
GR control
Utreotropic effect
No. of deaths/mice injected
Mean score
Basal control
Rate of reduction
PCP activity
K5
Relative stimulation index
deltalog10CCID50
Min oral dose
ED ratio
HC50
kinact
Analgesic
VOLSYN
Average colony count
Active
ILS max
CCID50
Platelet
Vacuole response
Max Uosm
Latency time
Retention
Pancreatic response
Mitotic index
Stability
Rate of hydrolysis
I23
k cat/Km
average log GI50
Body weight In. / Fi.
Therapeutic index 99
No. of errors
Residual binding
Rescued neurons
Index
Mean tumor volume
Catalase
Prodrug reduction
EDmin
Decrease in blood glucose
Acceleration
Log KL
Ka(T4)
Liver CH levels
Ouabain
Max fall in blood pressure
MABP
Hours above EC90
Max delta FC
kDPPH
Max collateral index
RF
DTT inhibition
Increase in plasma amylase
NO2- (mol/mol)
Z
IUP
U/P
S/Cereb Ratio
Activity B
Inhibition tumor index
C1
RT50
F3/4
Simulation
MPC/MIC
BSI
Zone of stimulation
Tox50
Mean duration
QH
Kb app
Fana
alphat1/2
Reduction in RBS
Formation of compound
Protective dose
Average turns/first 15 min
Reducing activity
A10
Variation
No. of rosettes/100 Jurkat T cells
PGI
MC100
D-2
-Log IC50
Calcium release
CIp
Delta RBF
Median tumoral volume
Body weight reduction
Replacement
Dose/g
T/C-CQ
Edema
CFR
DNA fraction
Flaking score
60-day survivors
-ln K
Summation MABP
Xi50
DeltaBP
KI'
Ki inact
No. of relapses
Change HDL -C
PKa1
1/2Kcat/Km
Ratio CC50/IC50
Density
T1/29
2x TT
Toxic effect
ID50 ratio
K ass
Tumor free survival
Mean no. of lung colonies
Delta Fmax
Asorbance
Ratio of dose
Plasma lipids
Response rate
Pregnant
Log K'W
K inact/Km
Phototoxic effect
Decrease in Bmax
BCM serum Ca
Lethality
E2
Recovery rate
Cardiac contractile force
C/I
Postdrug
Ulcer index
Depolarisation
HF ratio
HA release
MISS T/C
CMC
Response ratio
Induction of catalepsy
Relaxed DNA
KD non ionic
Protective effect
POE score
Protected mice
UN
Intrinsic Toxicity
Synaptic site
Threshold concentration
Excess MST
Log 1/LD10
MNCC
Kin x
MIC50/MIC90
k3/K1
Death
Average skin reaction
Alpha E
IE1
Relative inhibitor potency
Dose ratio
MAD
kb
Relative ET-A IC50
Dilation
ILS (Sur)
Eye toxicity
Depletion
Selectivity coefficient
Delta Ca
Post drug blood pressure
Transcriptional activation
Serum total cholesterol
EC20
CyD50
Max decrease
Net cell kill
Occ50
Log beta3
Log t1/2
Symptoms
p alpha
ID90
ov. rat/total
Max non-toxic dose
-Log C
Fmean
Csat/Co
Internalisation
ERP (delta)
Kbb
Jump latency time
Unbound
Cures@ 40mg/kg
Alphax10E
NO release
Lesion coverage
Level
Stimulatory effect
Sensitivity
Avoidance time
ED2
Lung weight
Kt
MET
DA level
Communicating cells
ABBC
Peak deltaHR
Monocation species
D2 duration
Antiemetic activity
Separation
Response unit
ID95
Benzidine positive cells
Amount
Behavior response
Relative activation
Hemolytic activity
P2 uptake
C10
Antigen p24 content
Conc_plasma
Average survival time
Topical potency
I13
DOPA level
Max delta BP
Time above IC50
Drug period
Tp
ICD
Prodrug reconversion
Ki/K'i
MGM
% remaining
Delta TAO
Initial_rate
Dose excreted
Log k
Mean log GI50
Skin uptake
Time to max. BSR
CL/F
MDR
Activity (mg)
Kimut/Kiwt
L-T3
AUC 1/T1
Tumor-free
Vmax / Kmax100
Inhibition activity
Cp
No. of dogs used
TW
pKi
Emesis_Cmax
-Log K
Agonist index
Km x10e3
Log [-5]
RH/RL
PAE
FRP C20
T/C 1
Overt behavoiur
IP3-sensitive Ca2+ stores
Mean day appearance of lesions
EC99.9
Ulcer incidence
Log ESA
Rel potency
CS50
Tissue swelling
Log PR
Blood clearance
Log 1/ED30
Swimming activity
Phorbol displacement
Max delta MAP
Anticonulsant activity
pKiL
Phagocytosis
Residual contractile activity
Time constant T1
Relative threshold dose
K SH
Change in DA synthesis
Residual amine (ee)
Antidiuretic activity
Log ED50
Hypoglycemic activity
Rate of hydride transfer
Inverse relative potency
Diuretic effect
IO
PG
-Log Sw
Concentration_Plasma
Max fall in MAP
DMF
Hydrolysis rate
Myoblasts with parasites
Rating
ED70
Lag time
Prolonged VRP
Flu intensity
Apparent_pKa
No. of canine
Molar equivalence bound
Diuretic effects
Cell toxicity
Survivial / total
Radioactivity
Aneuploidy activty
Analgesic efficacy compared to epibatidine
Lesion score
RHT
Relative dissociation rate
ED99
Ctau
cGMP content
Other
Relative rate of decomposition
Max hypotension
Average 14-day MGR
Delta CPP
Ki/ki
K DMPC
Tumor growth inhibition
[GSH]
Vp/F
-Delta G
Traction test
Relative cytotoxic activity
Activity in animals
Level in serum
Reversion activity
DBP
CL_renal
Melanotropic activity
Bone damage score
pIC100
Viscosity
Serum HDL-cholesterol
Total glomeruli
Albumin
Molar primaquine Index
EA
Presynaptic antagonism
Phototoxicity
Net dry weight
ER max
TAD
log S
Change in blood flow
Weight change on day 5
packed cell volume
Delta HR50
Activity (umol/mg.of protein. min)
Antagonistic activity
Relative tumor growth
IS
Radioactivity remained
Phosphorylation rate
pA50
pH1/2
Thermodynamic solubility
pIC50(mM)
Kidney weight
K OX
Pressor response
Log TCID50
LDL oxidation
CLtot
behavioral observation
-Log LC50
Symptom initiation
Ventricular relative refractory period
TC50/IC50
GDP ED50
Toxicity related death
Cr secretion
LD app
LPS
K act
EC100
Max dose
Relapses
Delta HDL-C
Survival range
Potency index
Max fall in IOP
MIW
Oxygen consumption rate
Sweetness potency
Saldiuretic activity
Amount bound
Brain/Plasma
PBI
3 log kill
Decrease in No. of avoidence responses
AIDH activity
pA2
Decrease in heart rate
Distribution ratio
No. of axonal branchpoints/cell
logMIC
IC50
Fraction of accumulated 86Rb remaining.
RVR
DNA damage
Tubulin binding
Suppression ratio
Delta non HDL-C
G1
Permeability rate
logCL
median survival time, days
Apoptosis index
Mean log concentration ratio
Licking latency
Mean effective dose
ka
Selectivity in binding
Cell density
Na+ restoration
Delta IOP
K+/Na+ ratio
No. of rats with 5-HT syndrome
LTS
PT
Log ILS max
T/C 41
MLD
LD50 x 1/10
Relative resistance
C10APD90
UTC
EC95
Gated current
Staining
Inhibition period
logKA
CFU-GEMM
SPAV3
No. of invaded cells
Observed [pt]
nKa
WBC x10e-3
Ratio pIC50
Max activation
Cholesterol reduction
DRF
MED50
Delta A/min
Connectivity density
Dry weight
Significance
Blockade duration
Decrease in MABP
Culture negative
No. of escape failure
AUC Npo
SPB
Metabolite levels
Sleep time
Urine Na+
K'i
Deiodination
Excretion rate
Serum total triglycerides
Distribution
Incorporated
No of monkeys
Change in MABP
Relative growth
dose BP/BP
Fluid
Reversibility
Weight ratio
Avoidance response
DA release
Injected dose/organ
EC50
AD99
Final average tumor weight
Membrane integrity
T bound
Helicity
Arrhythmias times
No. of survivors
ILS40
Ulcerogenic activity
kn
Log P16
Negative ionotropic activity
Thy-1 expression
Positive
Log 1/D50
p(1/MIC)
MMC
delta Vmax
Intinsic activity
Inhibition potency
Lowest effective dose
Half duration
CCIC50
I20
RHR
P-450 loss
Drug responding
ED delta
Time in flight
Photosensitization
MeAIB uptake
OT interval
ED33
Lysis time
Min antiviral concentration
Anti-fighting behaviour
Active/total
Median toxicity
Gastric lesions
Aberrant cells
MHC
Relative uterus weight
MIC99
Serum Mg2+ level
XI50
%LBF
Free radical scavenging
Delta BG
KS
Relative hydrolysis
Log 1/ID50
Anticoccidial Activity
Log 1/KL
Mean tumor atency
K4
Tissue area
Bmax2
HD100
ID99
Cmin_PBMC
Kinase activity
Hydrolysis
Min lytic concentration
k3/k1
NBT positivity
Tumor growth
Selectivity
Agonist effect
Ratio LC50/IC50
Seizure stage
Duration of reversal
ionization
PTZ
Blockage activity
Rotorod index
Papp e-6
Mean enhancement of binding
Urine K+
Log TA98
Max contractile activity
Change in cell number
CPE index
CPD50
GE
Virucidal
Ibuprofen
pEC20
Max rev
Delta plasma cholesterol
eLog D
K-2
Carotid flow reduction
Reversal
Safety index
% reduction
Reactivation
Delta SBP
APD50
Mean RBF
Log Ko
Carotid Flow Decrease
Tubulin
Colonic weight
SUV
AlDH activity
rf50
Total urine activity
DLBT
Enzyme inhibition
MG-MID
Relative SEAP activity
Proportion of survivors
Antibody titer
Cell kill
Cleavage
Arterial occlusion
Uptake at C50
Max release
delta Log P50
Stretches
Hypermotility
Stimulatory activity
I42
Blood lactate
pIC30
Activity (nmol/mg.of protein. min)
AD90
Relative stimulatory activity
TDS ratio
NADPH oxidation
PkB
Judgments
LD0
Muscarinic receptor affinity
CCTD50
Log 1/B+100
Rotational behavior
Optical density
ED10 HR
log(10'3/IC50)
Lambda-ex
AFLCl
Kc
IC50H
Urinary excretion
pH
Transport
E
Net log kill
T3
A/Ad
Imax
PC
Functional profile
Ratio ED50/MIC50
Contractility
No. of mice effected/No. of treated
CT1
ppKb
Velocity relative to ATP
Ke selectivity ratio
No. of mice dead
Pro/Min/Enz
BDW
AUC first treatment
Reduction in virus titer
K DMPG
P
Survivors / total
RT
Rotation number
IA50
Activty
Lipid peroxidation
Mean body weight
Glucose normalisation
No. effective
No_cures
LogPapp
Change in response rate
AUC N
Radioligand bound
Glucose
Of tumors
Vm/Km
Max delta
CT50
Liver concentration
Sinus beats
Antimicrobial activity
Clinical reference
Weight
Hypersensitivity factor
Precursor inhibition
Necrosis
BAT
s-GOT level
KinX
DNA peak exclusion
Relative EC30
Geometric mean
Alpha-lipoprotein cholesterol
E50
Change of body weight
pAlpha
Antibiotic resistance
S-phase
Relative phosphorylation rate
Parasitaemia
Extremes treated
No. of mice protected
DC
ED3
Relative Selectivity
Final plasma concentration
KDNB
Max effect
Time spent
pKa1
Relative antitumor activity
pIC25
Mean ED50
Hepatocyte stability
Complete remission
BP increase
Fold-induction
Boron in media at 0h
[3H] thymidine cpm/dish
C175
RIC50
AUC glu reduction(mM x min)
damage reduction
PCaco-2
Cellular content
Log M50
Mean axonal area
Cell no/dish
Block
Vinact
T/C survival days
Delta t
DR10
pRA1
Plasma [14C] cholesterol
pRA
CE logK'
ACT
BUI
Mean pit size
Ratio pA2
Prolactin treatment
Ki obs / [I]
Frequency
MDH Reactivation
Periosteal mineral apposition rate
Deaths/total
A50
Reduction of prostate weight
(kcat/KM)/kuncat
Log 1/LD50
k-1
F
Daq
Time to 30% BSR
Delta cpm x10e-3
Km/Ki
EOS inhibition
Therapeutic indices
NA
LVEDP
Sensitisation
Recovered in urine
AOC
Dose elevation
behavior
Bapp
K ACT
Maximal activation
Inflammation units
aPTT
Relaxivity
Cytochrome loss
Relative liver weight
KB
HACU improvement
Mu/kappa ratio
XL50
Nitric oxide
K B
Chemosensitizing activity
DeltaTm
Test
ME increase
FR10 treated
MNTD50
Antiviral selectivity
IC5
TD50
% change
Adduct formation
General activity
CT5
Suppression of parasitemia
FR10 control
Decrease in fighting
LDH release
Analogue level
AdoMetDC
Gross kill
pA1
SD
K amine
Dispacement
Dioxygen uptake rate
Enhancement ratio
M2/M1 Index
Duration of seizure
KD app
Remained
ID
Cmin
T99.9%
Score
APD60
Paralysis
Initial rates
pC20
Severity mean
BWLmax
Max
MOT
Ki int
Mean no. of revertants
Uterotropic activity
Quantity
Central selectivity
Locomotor activity
Binding affinity
ED50 / ED50 (taxol)
pLADM
%
Ventricular tachycardia
BSA binding
Efflux Ki
AH interval
Kiact
Log delta (1/T2)
Radius of inhibition zone
Binding energy
RBA
Resistance index
Css
Clonic seizures
Max aggregation
K+ excretion
Mortality
MPD
Challenge dose
Plasma lipid level
Edema ratio
ID/animal
METD
Growth inhibition
Ki(app)
Papp
[I]
FS-SIF
RCI
Efflux
Clones
Variation of edema volume
Culture
pK1b
Control growth
Reduction in movement
Cardiac depression
Mobilization
Modification of adsorbed drug
Vmax(app)
dPT
K x10e-5
Ratio pKi
Ratio_tumour/plasma
Plaque accum
Skin Graft Survival
ED100
Corpora lutea
EC90
Activity remaning
Relative loss of potency
k2'
PCMA antagonism
K app x10e6
Derived trabecular number
Log GI50
Extent
% of selectivity
Affinity
DSB
Lowering
TD
pKa BZ
Carboxylase activity
Relative uptake
No. of sensitive animals
No. of mice infected /total
EC5x
Urinary recovery
HSF activity x10e2
Hepatic necrosis in survivors
Displacement
Exhibiting turning
Polymorphonuclear cells
Glucose uptake
EC30
Original amplitude
pA10
Relative TS
Average uterine weight
-log(RatioIC50)
Delta beats/min
COF
Margin before onset of tachycardia
Lysis area
Fraction cured
Caco-2 permeability
Writhing number
Median retension latency
NTD
Parasite_Clearance
Relative change
MNTC
Intensity
Fecal weight
Content
pKa AZ
K1
QTc Interval
HF
MRF
Catalepsy score
MIC
-Log IC50/IC50
Assembly
Diffusion
P value
Survivors at day 8
S
Delta
Cells
Log Ke
No. of rats with lesions
Duration of plateau
Plasma integral
% of control
ITP
RBC
Activation
Activity rating
HD40
MCD
No. pregnant/mated
Ksolv
MTS
LLR score
Km(app)
No. of survivors/total
ILB
pKact
d tox
Adjusted Ki
I.D./g tissue
Anti-HIV activity
Ferret emesis
Survivors at day 30
C1.3
Km'
I/E
T/A
No. of guinea pigs protected
Prolactin control
C/T
Insulin release
Total activity
PDR
Log [-9]
Minimal bacteriostatic concentration
Decrease in life span
Rotorod
rT3 Production
SEC50
Ki low
MST increase
Conversion rate
DeltaTC
Transfection activity
inhibition (at 100uM)
MG MID
Fold resistance
Log k'o
NOAEL
Result
pKa
Peripheral restriction index
Occulations
Relative oncentration
Max SBP
Log K-1
LC30
Thymidine uptake
Imbalance
K inact
pkb
Inhibitory potency
Potencymean
No. of dead mice
Topical irritation score(0-21)
Human potency
I10
GID75
k+2
PI hydrolysis
Average onset
Ionization
Log 1/D125 (mM kg-1)
ED6
Thymolysis
Log KB
RSA tR
Log AC50
Reactivity
ascites volume
[3H] thymidinecpm/dish
Ratio Ki(app)
F1/2
Vss
FACO Activity
Max delta APD95
No. total
No. of mice cured
Vz
Minimal dose
MTD
Mean aortic flow
Lambda-em
NOEL
Formation of NO2-
Survivals
Antihypertensive activity
Agonist response
Log 1/Ki app
WLC PRA
Relative uterotrophic activity
EPS
Serum cholesterol
T.I.
Lactone
PKa
ID/g femur
Antiuterotrophic activity
Iron change
c90
Enantioselectivity coefficient
Tumor inhibition ratio
Relative thymus weight
Responders
Glucose correction
MLS
No. of untreated cells
%max
IPol
Plasma half life
Growth Inhibition
Pigment induction
Remaining
Binding inhibition
pC3
x fold
No. of mouse protected
2 x APTT
Kinact/Ki
Cured animals
Median T/C
DNA on filter
Tumor mass
Threshold active dose
Total
Luciferase activity
Secretion
K Bapp
Drug deaths
GSH level (mg)
Blood sugar lowering
HT50
Max delta FRP
Mean survival in days
PDC
HTS data
M.A.D
Oral dose
Survival dose
VI30
Log ratio
Log kw
Beta-lactamase induction
RTG
log10CFU/g
Organ distribution
No. of implants/pregnancy
AB
pKa5
Kpot A,B
Decrease
pKabz
Amplitude
HF2
Binding site preference
ER
DR20
Relative seminal vesicle weight
BBB Impermeable
MED10
Relative hydrolysis rate
Lipid level
AE Score
50% naproxen formed
Amount of TXB2 formation
Inhibition at 5nM
kr
SVT
Uterine weight
Accumulation counts
BP (ED50)
2x APTT
Remains
Analgesic efficacy
c30
PTZ seizure
Behavior score
Ratio LD50/ED50
First adverse effect
Virus rating
Free complex
bwc
Iron clearence
Average consumed
Opsin shift activity
Toxicity index
pLADy
n/N
Max reversal
Migration
Growth_index
Hemolysis
EC2
IL-1 production
AZT formation
Platelets x10e-3
Analgesia duration
McPhail index
Developed tension
pKa3
PL
Apoptotic cell
Affinity ratio
Tumor response
EC5X
TGI50
No. toxicity/tested
EPS MED
Restoration
POT vigilance
Log PTA
G2/M
Relative to DA
Mean inhibition
log KOW
Max inhibition
RI
TE50
No. of axonal branch points/cell
Uterus effect
Ulcerogenic index
Log RA
Max respose
Count
Fa
Taste class
Presumed drug-related deaths
135
Survivors at 24 h
CC50
Acetaldehyde
Survivors
Plaque reduction
Behavioral syndrome
Solubility ratio
Tested/Control
Delta mmHg
log Kp
Tp control
M/T
5-HT syndrome
T1/2 beta
Substrate specificity
Peak effect
Vasorelaxant effect
Brain levels
No. of metastases
Biliary excretion
Load
mequiv of Na+/kg
Max inhibitory effect
TOX/TEST
Average seizure score
Stool output
Loss of cells
Relative to control
Mice In. / Fi.
ED125
% NO2-
MIC+/MIC-
AB50
GDPactivity
VM
log10CCID50
Average weight gain
Log Kd
TOC ED50
PWT
Morphology
Influx
Toxic deaths
MED90
Nitrite
Body weight loss
Change in body weight
BG
PO2
Max mean weight loss
I40
EI
RLU
TAI
Relative binding potency
rapp
Delta FFA
Testosterone
%Bound_Albumin
T2
KD hydro
Bacterial growth
Toxic index
No. deaths/treated
Mean relative surviving fraction
% injected dose/cm3
Sensory evaluation
Papps
D150
T/C (d)
Glucuronidation rate
Cell plating efficiency
k3'
Superoxide anion
FIC index
Tumor incidence
LV FRP
No. of counts
Khd
sigmaH
BWL
No. of uptake sites
Log 10 cell kill
Proconvulsant action
Effective dose
P ratio
log10CFU/ml
Intrinsic efficacy
Correct responses
Saluretic score
Chemotactic index
Relative F%
Average latency
I / E100
Peak radioactivity in blood
Retention time
IC
Cumulative dose
Hemodynamic change
Flow rate
Min concentration
Oxidation rate
Treatment period
Triglyceride correction
TBMIC
Mean uterine weight
HSAI
M2/M1 index
No. of cures
Counts/30 min
Mole fraction
Brain lesion
Mean no. of days post-infection to death
Dose per organ
Lysis
D50
K alkyl
CF C20
Quenching
RLU/well
Activity of control
Intrinsic_solubility
Growth response
deltaTCID50
Differentiation activity ratio
C50
Horizontal screen
Change in tidal volume
CD100
Max temperature decrease
VCR accumulation
Pleural fluid
Kq
Atrial MAPD90
Max change
Cell Survival
Inhibitory response
Relative potency
Blockade effect
Tissue distribution
Growth zone
Dose-modifying factor
EC50 ratio
Ionotropic activity
Pw
Net Swelling
Falling
DOPAC concentration
-Log MIC
Hematocrit
P24 concentration
MI0.5
K L
Ri
A1 selectivity
Log CR
Acetylcholine level
Efficacy ratio
Mortality inhibition
Trabecular no.
ID/organ
BP change
Of dose excreted
No. of sensitive
BBC
Med tumor area
-Log K0.5
Baseline
Activity A
-logMIC
pD10
mean log D
MIC80
No. of animals responding/animals receiving drug
DTH
IP+SC score
Emax
Prolonged ARP
Excess zone radius
K second
Plasma glucose
Change of HR
Log inhibition
MES
Cbrain
Mean excretion of Na+
No. of plaques
CTL activity
Cp max
T free
PIC seizure
Affinity state 2
Wet weight
Med tumor weight
FPT
Modification
EC50rel
Delta blood pressure
Excretion
Differentiation
ERP observations
PRL
Infertility activity
Log kOH-
Delta I/I
RAP
increase in temperature
PEI
Inhibition rate
ED (1mV)
Mineral apposition rate
Krel
K beta
Fungicidal
Log TCID50/mg
Mean survival days
Platelet count
Maximal relaxation
O2 consumption
Specific binding per mg of protein
Log Phep
Log 1/IC90
Mean reaction
Max decrease in blood pressure
Reaction
Volume
log10PFU
Ca2+ current
Rate of O2 consumption
FI5
Cytotoxic activity
pKp
Epinephrine level
Ki/KI
C20
Log net cell kill
p24
Cytotoxity
ED97
CMP
Change of tumor area
CFU
[Ca2+]
Ca2+ transport S/M
LDL cholesterol
NB
Atherogenic index
AV block
-Log K B
PAP
IC0
Substrate metabolized at 1hr
Relative susceptibility
Survival after 10 days
Exudate volume
Hypnosis duration
Log EC50
10E2 k1
FRE
Control response
Blood loss
TC
Change in entry latency
3H-TdR incorpolation
ME
Threshold current
Displacement of DP
Average change in body weight
EC0.01
Vmax / Km
Complete survival dose
K obs x10e2
% release of nitric oxide
Log2
HVA control
Cumulative urine volume
Fallen/treated
Max PI
V
Normal beats
CPA
Log P/Log D
LA
Fold_reduction
Adjuvant activity
Erythema intensity
Survival time
Lysozyme release
Inhibitory activity
NADH oxidation
H2 activity
Injected
Km app
IAR
Onset for sleep
Delta MAP
Cmax_[GH]
Thymidylate shift
T1
Dead/total
AUC/dose
Mean response
Platelet count/ul
CMV yield
Denaturation rate constant
Apoptotic Activity
Km/Kcat
ECLT
No. of animals protected
Induction number
Learning time
Antitumor activity
TSH/chol
Plasma GH release
Log TA100
Min lethal dose
pED50
CIC90
Control value
CLup
Histamine level
ToxD/Surv
MTD/16
kred
Selectivity rating
K'
Cage leaving
Prostaglandin E2 level
AAL
Toxicity Survivors
Concentration_urine
Exhalation of 14CO2
Bullatacin index
Gross log kill
Relation
pKa,1
SA
Change in mean aortic flow
CC50/IC50
NED
Pe
Crel
Post Antibiotic Effe
POT
Relative IC50
pA2 - pA10
CBF-ID75
I5
Tumor volume reduction
Serum lipoprotein cholesterol
Ear thickness
K''IAM
AUC ratio
G30
KII
Mean weight
Log K'w
logKi
GSH
Therapeutic efficacy
Amount of unreacted substrate
Serum glucose
Ki/(Km/Kcat)
SCW reduction
Seizure score
2T11
Kix
Pka2
PI turnover
Log 1/E50
Fibril formation
3.3
Prolongation effect
Aggregation
Carbonyl group
Neuroprotection
MAC reduction
High
Vd
Mean excretion of Cl-
IMPDH activity
CPM x1000
Reduced food intake
Production
Log MBC
Increase (Emax)
PT extension
GRI
Po/w
Degradation rate constant
No. of crosses
Delta logS
fT>MIC
Extent of DNA binding
Choline uptake
Relative esterase susceptibility
Log M
D
T/C max
Cell no./dish x10E3
Average peak Concn.
IP
Relative binding
Removal of microfilariae
Improvement
Total turns
Peak current
Serum triglyceride
Dissociation ratio
Log KAT
Length
TN
Bile flow
Speed of induction
Rotations/10 h
IFI
NE
LV DRxHR
FPTase activity
pChange
pCC50
Cmax_unbound
Virus titer
Absoption
Hypocalcemic activity
Max response
Bactericidal
Vmax/Km
MES/TEST
5-HT Level
pKA
GPT Level
Change in MST
1/Ki
Fold reduction
FBF Ratio
Enzyme activity
TC lowering
CIT
KDMPC
Log 1/delta/Ca
Log Kw
HPB
Injected dose/g
Water consumption
Survival
Delta S-H
log(1/C)
Decrease in heart norepinephrine
EC12
Plasmaconcentration
Bacterial counts
Viability
Tubulin content
Ratio_Cmax_brain/plasma
Relative ED50
delta logD
MTC50
% recovery
Control relaxation
pDelta IOP
Fold reversion
Proliferative response
Acid hydrolysis
k_on
Drug discrimination effect
No. of ferrets
pEC0.5
IFN
Agonist potency
Threshold value
Antipsychotic
No effect dose
Hypotensive activity
Hyperglycemic activity
R%
Change in LV dp/dt
Sleep latency
Am
Liver weight
T1/2 h/min
HCR
dp/dt(max)
Approx. lethal dose
Erythema induction
Deoxyribose degradation
Vbeta
CTF
Dose/ml
Binding constant
Conversion
No. positive cases/tested
Reduction in TG
Onset for sleep, min
Terminal elimination t1/2
No. of circlings
Gross morphology
ICA
No. of lung lesions
CTS
deltaA
ED50 ratio
Velocity
Drug response
GH peak
Max lowering MABP
Total protein
Kdiss
Irreversible binding
APA
Delta APD95
Enhancement
Log K
ECAR
Interferon response
ED1.5
Feed efficiency
Rel max
k2/KI
PS
Serum conc
C50g
Midpoint dose
Biological activity
Log concentration
Total binding inhibited
BK
Cure rate
nHill
Amylase stimulation
Initial blood pressure
Degree of cross resistance
IC60
Mean increased life span
HbS solubilized
Delta/kappa
Oral activity
Cell proliferation
IS/AAR
Specificity
Increase in IC50
Ks
Net accumulation
SD200
Ovulating rats
Sni
Survivors at day 28
No. of dead animals
Iron output
Activity (umol/g.of liver 75.min)
Cures@ 20mg/kg
Inhibitory ratio
CAT activity
AI50
CFC20
Decrease in the QA interval
Primary response
Residual secretion
Ki 0.5
Iron mobilized
DD
GSH-Px activity
Day of vaginal opening
P7.4
V1
Tubulin polymerization ratio
Adjuvant effect
Change in Cl- current
Ke
Thr uptake
Log MrI
rel T
Min ED
Delta IC
%hepatic blood flow
grade
Infected
ISC
Log KA
HED
Median
2PT
ID80
ID/brain
E/Emax
kin
Cholestrol levels
Triglycerides
pFe3
Oxytocic activity
[LDH]max
Injected (dose/g)
Cmax
apE
Histopathology
pEC0.5,diss
Delta MA
Bronchoalveolar lavages
BPR
Bmax
BT
Tracer
pKred
ED Arec
pIC35
Of rats turning
Permeability
% of NO release
Log 1/MMIC
Emetic episodes
30 day survival/total
Death dose
dP/dt20
ADD
Relative maximum
Impaired
Collapse time
KIs
ID50 mg/kg
HVA
AG80
Viable cells
No. of animals protected/animals tested
Kuncat
2aPTT
pWeight change
Fever response
Net turns/min
Fmax
Leishmanicidal activity
Cytocidal activity
Saftey margin
Activity index
MID
IC90 mutant/IC90 WT
Analgesic activity
Rate of decomposition
AERP
Extraction
Inhibitory rate
Delta HR
AAC
Infection score
KOH
Log potency ratio
Fold activation
Reduced BP
Duration time
Lethal toxicity
IVP
Max dV/dt
K bind
PKb
ED200
1/kmax
GI
Decrease of SBP
Colony_count
Binding potency
Stain index
Increase in blood pressure (P/R)
Protective ratio
Lipophilicity
Tumour_[5-FU]
log10cfu/day
Survival extension
Differentiated cells
Metabolic rate
Log I50
Co
clogP-logP
Log cell kill
Fecal recovery
Max uterine weight
PLT
LC100
GS
DOSE
Kiso
Ca2+ reduction
Max enhancement
Change in temparature
Plasma total cholesterol
Ki(1.8x10e-11)
2-DG uptake stimulation
Relative protection
fCmin
Directly measured thickness
Complex_formation
PP2A Selectivity
Cmedia
Specific Displacement
Mean graft survival
Analgesic efficacy compared to morphine
Oligo shifted
Rate change
Plasma content
Eudismic ratio
Logit_p(conc)
Activity regained
Kr
Apoptotic activity
Radiation prot
Tolerance
Physical dependence capacity
Kinetic constant
Myoblast with parasites
N
pI50
Change
Tumor weight
Total radioactivity
K+ Ion content
Fluorescence Intensity
ID50
Relative value
Level of cGMP
Urine/bile
DLS Concentration
PL-017 shift
LED
KD'
Antagonist potency
CPE50
Intrinsic
Anti-arhythmic
Behavioral response
DHP-I stability
Change in MAP
f %t > MIC
Tumor/liver ratio
LD30
C
Cured/Infected
Erythema
Ambulation score
pKa4
Tt
Excreted glucose
Tumor volume
-Log Ki
Receptor binding
NOHA
pKiH
pKP
Limiting t1/2
Vagus
Clast
CC20
Mean survival
Glucose utilization
pTD50
Km
k-2
Plasma-E2 concentration
Kpol
Log PNalk
Neostigmine reversal
pA2 app
Erosions
Decrease in activity
Radioactive constituents
No. of lung colonies
Negation
TCS50
Block time
Time after dose
Protection index
Transporter deg rate const (k)
No. protected/tested
GST activity
Cardiac frequency
Dependency
S/CX Ratio
SGPT activity
LV dp/dt
REC
RNA fraction
FR50
Relative Potency Ratio
No. of platelets
WBC
log Pe
Rats turning
2x aPTT
Excreted
Fold selectivity
Progressed tumors
Molarity
Cure
Amount of metabolite
Koff
No. of cured
KBp
Mortality ratio
T/C @ 20mg/kg
Suppressive dose
No. of living cells
TI rating
TID20
Protective activity
Thromboxane B2 level
Optimal dose
kAH
Log Pmic
HSF release
Translation
d50
Zone diameter
Esc loss
ED1/3
I28
Hepatic cholesterol
Reversal activity
TG100
Relative lipophilicity
Alkylating activity
Estrogenic effect
Log 10 LC50
Average weight change
Endosteal eroded surface
E/Eref
C10 N2
Cardio selectivity
EMax
Improved
Max reduction
BPI
Selective index
Liver TG
pKi ratio
Ip
ki/Ki
([I]/[S]0.5)
Kreact
DNA binding
Delta weight
log10CFU/ml/day
-Log activity
No. of killed or paralyzed
Antibody stimulation
DNA fragmentation
G0/G1
SF
Biodistribution
K21
Ouabain dose
ClM
Rat fertility
Infarct volume
[3H]-uptake
Exp Inhib Constant
Remaining compound
T/V
Urinary level
Cortical infarct volume
Na+ ratio
Log CFU
Change in body temperature
FT mean score
Change in heart rate
k-1 app
Relative Bioavailability
I/C
Dopamine level
Maxi-K current
Survivals / total
Tumor/blood ratio
LM
Animals affected
Relative efficiency
Inhibitory binding
Vdss(app)
Vocalization time
Reactors/Test group
Serum stability
Response
P ABC
REP
Mean LAF
CLIP
Pc
Heart weight absolute
Possible response
Active dose
Log 1/ED50
Mean value
Pgp AbA/analogue ratio
LDH
Growth of cells
PF
DBP change
Selectivity ratio S3/1
Radioactivity level
IA
No. of mice dead/day died
CLH
Decrease RVR
Cell size
Elevation of threshold
Migration index
Erythroid induction
Writhes
MTX equivalent
LogP app
K app x10e-7
Actvity
No. of spikes
CFR rating
Serum creatinine
Morbidity
Pmax
CF
Duration
Fu
Toxicity ratio
Average lesion score
INH
Onset
Rolipram activity
RBA2
Glutathione levels
Ki ratio
X
K3
A ctivity
Urinary glucose excretion
Latency
Systemic effect
increase in RFU
Supression
Glycine antagonism
DC50
Log 1/D125 (L1210) (mM kg-1)
GH AUC 0-180
CI
pEC50 diss
Control vomits
K-1 decrease
Acid secretion
delta logP
Cell number
Prolonged QT
CO
Initial inhibition
Change in myocardial conduction
Extraction ratio
TG
10E2 K1
LD/ED80
Uterus to blood ratio
Covalent binding
Relative ODN uptake
Max reduction in mean arterial pressure
Selectivity quotient
Anabolic activity
Excretion Na+
[3H] concentration
1/n
No. of mice
GMMIC
DA/NE ratio
Sterility
Max agonist activity
No. of axonal points
Specific index
TGD
MDL
Ka app
Loss of activity
Dissociation constant
Prolactin release rate
Receptor state
Mean excretion of K+
Free fraction
Log Palk
logKd
Injection dose/g
HYPO
Toxicity (deaths)
Time of licking
IH50
FPT msad
kONOO-
Log PI
NEA
ERP3
Radiation equivalent
Max/average
p alphaKa
H ABC
GR activity
NaCl concentration
Agonistic activity
Reduction in AUC
Ratio TD50/ED50
Plasma glucose level
Of HDL-C
2DG uptake
No. of protected animals/total
scMet
Time to peak tension
GABA enhancement
Change in cAMP
fc max
RBA ratio
Serum Ca2+
Reduction in heart rate
MFC99
Activity remaining
Cleavage rate
Mean rate constant
Max intensity
LD20
Median life span
Experimental DPM
MTD50
Max IOP reduction
pGI50
Lesion_Clearance
Unchanged
TPR
IC95
Cells arrested
Intrinsic vasorelaxation
ln Kp
DNA cleavage
Log EC50(uM)
Plasma_[5-FU]
Log k' w
PFC/splleen
Infectedmosquitoes
TMED
Mean activity counts
delta pIC50 wt-mutant
BG reduction
rel k
Exploratory activity
rel ko
Change in rat blood sugar
MIC90
P50c
Analgesic effect
Spermatogenic index
Incorporation
Degree of resistance
L
Vmax
Acute electroshock activity
Kcat
Negative chronotropic activity
Turns/first hour
Wet weight of tissue
Mechanistic reference
UD
EC125
K Tm
Phospholipidosis
-Log ID50
delta Log P
Revertants/plate
Protective index
PD 50
LT50
Liphophilicity
Mean increase in survival
GPGB tension
LogD7.4
LL
Relative inhibition index
Lesion index
pKa app
MAT
LBF
FBF
k'/k'+1
SRR
Serum corticosterone
Average sample intake
Log Kill
Desensitisation
Log cfu/g
Serum T4
Ext AUC
Residual activity
pLADY
Proliferation
Q
Skin reaction
Cytotoxicity index
MND
CT-luci TAR
TVR
ROR
Endosteal mineralizing surface
TF/P
-Delta G obs
Survivors / animals tested
K aff
Turns/1st
MED99
Surface involvement
VSV
GI50/EC50
CL_biliary
Pt
Delta FC
Duration of immobility
RA
Penetration
Fall
K diss
Fmut
Unchanged NDEA
Acceptor activity
LAD
A-selectivity
No. of foci per dish
NOEC
C50k
Total infarct volume
S/T
NM
Nuclear cataract
Delta T
Distribution of radioactivity
Weight gain
A/B ratio
K A
Pigment binding
EFF+/-SD
ED90
Inhibitory concentration
% nucleotide present
Protected/tested
Peak inhibition
Urine osmolality
-Log EC50
Profile
APD70
RAC app
Log TCI
IC33
Contractile force
Fold IC50
CTS increase
EC
Rel brain exposure
Growth delay (T-C/C)
GI50
ID84
KNBP
PCY
LDH50
Lactose production
Cytoplasmic vacuolization
Fez
AUG
Hmax
Femur weight
AUC c
GTPase Activity
Ca2+ excretion
LD
Kb
Receptor occupancy
Krelative
Augmentation
RL
Loss of affinity
KOX
Turns
CNS activity
Swelling
Hypoglycemic
Block of activity
NR
5-HTP accumulation
Selectivity factor
Max Achievable Bioavailability
ADP formation
Alpha-adrenolytic activity
Sp Max
N/T
pKa6
Inhibition zone
Relative luciferase response
B(DPB)
No. of animals alive
ILS days
Median day of death
88Y-serum
Ep2/2
Blood Pressure
EIC50
Delta H-V
Group performance time
-Log concentration
Punch weight/MPO activity
C1.6
ID25
Tail vein toxicity
Plasma level
Amount of Ouabain used
GI50 ratio
pEC90
Time
Ke ratio
Corr
NT
ILA
Resowing
UD50
Tubulin polymerization
Agonist activity
CV
Exudate
pI
Initial heart rate
K 0.5
Antifungal activity
Blockade
Hammett constant
Boron incorporation
cAMP content
MSIC
CV dose
GHI
GTP-gammaS Index
Weight gain or loss
pRA2
No. of cured mice
Number
C120
Decrease in CVR
Therapeutic index
RM
Protective Index
Uptake/Binding ratio
Aggregate
Ct
Mean number of parasites
Absolute ratio
No. of retches
Active culture
Alpha Ki
Fraction experiencing seizures
OD max
Sign free dose
SD50
Relative metabolic stability
DUR
cholesterol level
Ki app
Log KZ
Change in blood pressure
Hydrophobicity index
PD' 2
Tm
AWC
Total liver weight
pka
SER
Edema inhibition
Alpha
PDK
Average dose per organ
Bitter taste intensity
rIC50
Concentration of Cl-
-Log Kdiss
Log Poct C
HSA shift
Thylpositive cells/spleen
Heme loss
Property
Log 1/I50
Relative concentration
pkB
ECmax
MFED
Inhibition (alpha = 0.01)
ID16
Methemoglobin
Decrease in hypothalamus norepinephrine
DFMBMD
Average IOP
GM
Efficacy index
ED50 mg/animal/day
MP
Ki app (inact)
pC
Mean urine volume
Survivors at day 15
Water intake
Cell no
Total number of entries
Change in respiratory frequency
MES ED50
Plasma concentration
Increase in MAP
MPC4
Change in conflict
Animals dead
Absolute
Average activity
Catalase rate
Bioavailability Increase
Relative substrate velocity
Correlation coefficient
CPCC
k3/Ki
Relative Kd
AT1 affinity
Hypothermic effect
duration of action
MRT
Total binding
Hematotoxicity
ClT
Tissue level
T/C (survival)
IVR
Poct
Log 1/GI50
% binding
Blood pressure
Rate of death
Plasma Ca2+
K-1
Hill slope
Incidence_count
Change of body temperature
Complete spontaneous reversal
Body temperature drop
CE37
Serum creatinine conc
Ratio LD50/EC50
Vc
CTC50
Tissue weight
Relative agonist activity
Tumor size
Cellular concentration
Minimum single dose
ILS (mg/kg)
Picoequivalents of amine/10e6 cells
AHV
PPB
No. of vomiting episodes
Inhibition (at concentration M)
DOPAC
Affected animals
TPE
Kis
Control of P-450 marker
Kidney VDR
Bicarbonate level
Serosal/Mucosal Ca
Estrogenic potency
Antibody response
Tumor number
pEC15
BWD
pK
Inhibition of increase in weight
Reversing activity
Cmax_tumor
Occ90
T1/2 regen
MDS
Activ ity
Reduction
C24h
A2 selectivity
SH level
Cures@ 10mg/kg
Total excretion
Relativity
Max delta HR
Exclusion parameter
Caspase induction
AUEC
Kif
Kds
Tonic seizures
Ca2+ antagonistic activity
IC10
Control level
Log rate
T/C corr
Amount incorporated
PGE2 Level
Resistance factor
RAC
ED300
Max protective effect
No. of mice without tumors
Kbapp
CITH
Inhibitory effect
Survivors alive/total
Relative ability
CC90
Ya
Diffusion analysis
Brain level
Non-HDL-C
Positive paws
Terminal t1/2
Toxicity zone
Tissue/Blood ratio
PKB
Peak rhGH
T>MIC
Binding competition
Ac
pCB50
CDOG
Average proportion
Polyamine content
Change in reaction time
KPCB
RC10
Log 1/conc (mM min-1 L-1)
CC50%
RSA
GTP shift
ERP1
Hind-paw lick latency time
Gastriculcer index
Log DSF
ED30
Kw
pRatio
Transport rate
Virus inactivation
SSC
EC1.5
GTP-gammaS index
Time to righting
ED
Social interaction
Peak effect time
Low
Stomach
HR
Max fall
Mice
FR
[ALP]max
Equieffective dose
Complex formation
In/Fi
Growth rate
Activity Factor
Relative permiability
PD50
Anti-emetic
GII50
Non-specific binding
Max displacement
Min ID
APD95
Binding stoichiometry
Fold stimulation
OT
No. cured
Ability
G Index
Glucose rise
DA response
Ratio
Parent compound
Log [MrI]
Relative Fluorescent Unit
FIC50
ARP
Cz
Change in weight
S/N
Residual insulin secretion
AUPAP
Cardiotoxicity
Treated
Amount delivered
Tension
Substrate
Absolute turn angular/3 min
Diazepam antagonism
Mean peak APTT
Log Pdod N
k obs / concentration
Log cfu/g of tissue
Increase in heart rate
Spontaneous motor activity
Logit bioavailability
Increase in dP/dtmax
K'a
kOH-
V2
SR
Mean response/min
Boron concentration
Irritation
Average weight
EDMES(2.5)
cpm/million cells
AUC ED50
Ccellular
IC40
Change in TPR
RIA
Log [-10]
IG50
Organ weight ratio
Cyclase stimulation
Insulin-sensitizing activity
C90
LD10
CPP
Others
Cysteine reaction
K+2/Ki
RV
Alpha c
logBB
Relative differentiating activity
fm
Serum prolactin level
K cat
I/IC50
kc
Cell protein in untreated control
KiH
Volume of urine
Selectivity ratio
Average No. of metastasis
FC50
Static tumors
Inhibition of damage
MCT
Hgb levels
Incidence of RBC decrease
Left atrial pressure
Paw edema
QA
Log 1/ID75 (uM L-1)
k obs / 1
Vel rem
No. of animals with liver necrosis
UV
IC50 ratio
Radioactivity in urine
Myristoylpeptide
CAR
Hepatic Extraction ratio
Treatment
Reaction rate
Blockage
ALAT levels
Toxic level
Heart weight
Ratio AUC
CD
ID30
NMDA effect
Emin
Rice stem length
Mean
Tick action
LD100
Kun
SD90
G-protein activation
IUP AD50
KA
Body weight change
Change in response
Na+ ion content
MPR
Control retches
Mean ulcer index
MIC100
Mean injected dose/g
Amount of Acotine used
Plasma GH
SS
SDS
Basal GH
MBC
MAC
pA2-pA10
Blood urea nitrogen
C5a max
Log 1/ratio
MUD
pKa E2
NTD50
Melanotropic potency
Day 9-RTV
NAD
Remaining rate
kHOX
Amnesia reversal
AUMC
Maximum response
Change of size
Combination_index
Mitogenic effect
REM latency
Net body weight delta
Mean free plasma concentration
Total iron output
Degradation
Body temp change
I ABC
FRP at 10microM
pAD
Antiamnesic activity
GI tolerance
Second order
Diet
Max delta MABP
AHA
RBA1
Axonal regeneration rate
CMT
RE
T1/2
Antifertility potency
Relative bioavailability
Weight increase
DNA cleavage activity
k'o
APTT
Mean log LC50
eduction
Total DPM
CL_Ratio
Log kon
Mineralizing apposition rate
Potentation
Scavenging Activity
Mean blood pressure
No. of rats
Vomiting frequency
Dose/g of tissue
PVCs
Delta C urate / delta C insulin
Delta ED50
Mean KD
ED5
Growth
Ratio of depolarizing activity
Rat turning
NADH oxidn
Delta Vmax
AI
Binding site fraction
Amount of cross-linked protein
Monoamine level
ILS30
SP
DR2
Long-term survivors
A0
nH
Decrease in tone
NADH oxidized
logCMC
Transcriptional activity
Spread
Pcaco2
Light transmission
Eggs
Conduction
Log Pe,max
rK
Resistance ratio
Toxicity
Total turnings
C120/ED50
Vd/F
ED30 DBP
Hg
pKa AN
MAP
CLogD
pKic
Khydrol
Caco-2 Papp
AE score
k''
SI
Inactivation
O2 production
Sterilized
Log 1/ISA
-Log KD50
delta Log Doct-dod 7.4
EC50 iGC
Distribution percent
BA
Temperature
ID (per g of tissue)
Activity scale
Average peak Concn
Reduction of IOP
Max weight loss
fc max/MIC
-ln (MIC)
No. of Colony forming Units
30 day survivors
Log 1/EC50
Specific binding
Kina
AD50
NLCK
MBC50
Pka
pK1a
FICI
logCC50
CC10
P50d
Plasma levels
Survival treated
RPE
Effllux
Tail flick
REA
IOP
Acute toxicity
Ctt2
Max jumping rate
Parasite suppression
Tmin
Cardiac output
Organ weight
G index
Acute tolerability
Motor activity
Cytotoxicity IC50
LH level
Abortion
Bmax1
cAMP increase
Nature
No. of mice survived
kik0/Ki
Lipoprotein level
IC30
Catalyptic action
Resorption
K/10e4
TO
k cat/Ki
HR(delta)
Blood volume
GR50
EU
BQL
Residual peptide
k2
Reduction in arterial blood pressure
[35S] TBPS shift
ID/thyroid
Concentration_plasma
Stimulation index
Hydrogen peroxide degradation
Cytokine induction
DAP
Drug mol/base pair
No. protected/ No.dosed
EC75
I80
Basal inhibition
TMP.decrease
Lactate produced
ILS
Stimulations
Cmax normalised
CA activity
CL(%Q)
Volume distribution
No. of cultures active/total
Total tritium
MPA
kirr
Anesthesia duration
food intake
Monomer
ATP content
Mean arterial blood pressure
NBT positive cells
sigmaL
2x aPPT
Ki/Km
inhibition of control
Brdu positive
T-cell binding
IR
Prolactin release
Atttacks
Vm
CCh
Repression
alkaline phosphatase activity
Ref I oncostatic index
Vc/F
Reduction in EOS count
Log 1/IC50
Max MBP
Fluorescence
pInhibition
C100
Max agonist response
Rise HR
Uptake value
Vmax (uM)
Potency Ratio
Change in WBC
Pressor activity
TGIR
Kgmax
Potency
Cytokinetic response
E0
FSC recovery
HDL cholesterol
Fraction
Ratio CIC95/IC50
DNA alkylation
Fold shift
K Bind
Relative level
Log 1/B.5
FOC
Mean no. colonies
Log K1
Brain conc
Anticonvulsant activityAnticonvulsant activity
Contraction
Pressure response
Ulceration
Alkylation
pKapp
Arthritic score
Halucinogenic activity
Control survivals/total
[Ca2+] variation
MEC
Oxidation
GHmax
Cardiac force
Adhesion
ED95
Delta HDL
1/kobsd-ka
CC30
k
Reduction factor
K NBP
Locomotor
TDS
HDL
k1
Residual insulin release
Relative florescence
Sleeping time
Dose interval
IC>80
Antiviral effect
MAPD90
Antiuterotropic effect
Hyperactivity
LogD
Increase in dP/dt max
Cell
Delta pCa50
Optimal dosage
Change from control
Increase in HR
Occlusion time
Log Ka
Decrease in Systolic blood pressure
ED150
Initial concentration
TMSW
Cures
Acute TI
DDT msad
Time to onset
No. active
RTV
No. of shocks
Cellular growth
Log potency
UB
Amount of [3H]thymidine
Relative rate of hydrolysis
Increase contractility
Approx. pKa
Mean survival time
ED40
Relative activity
MSC
Relative response
Media area
KE
Off-rate
LAL test
Rats blocked
Cytostatic activity
Fg
ST
Metabolite level
Plasma half-life
Antagonist activity
No. partial
ROI
Serum concentration
Max contractility
Induced convulsion
DNA relaxation
dp/dt
Plasma clearance
Alloste ic enhan er (AE)
Intima area
Susceptibility
ALP activity
ST elevation
SWo
k_obs
Irreversibility
p10 MIC
K+2
PD'2
Distribution of excreted Fe
AUBC
pCB
Kf
Permeated
T/C untreated
Dose/organ
Topoisomerase-I activity
Dobs
Days
Csat
Influx Ki
IC200
k2/Ks
EC200
kmax/KS
Postjunctional antagonist potency
Synergistic effect
Efficacy
RatioGI50
pKa,2
Ki ss
Increase in DPM
Time constant T4
ka/Ki
Clonazepam
CMR
Anticonflict activity
Urine volume
Extension
Cures/total
TTC
Variation/Control
MA
Binding selectivity
Behavioral score
Taste
Metabolism
SB
Log D50
MRC
FSC
Median day of survival
Plasma selectivity
Mutagenicity
K calc
NSB
Rel Max FI
Glucuronidation
AUC units
Mean life extension
Lysis diameter
P (Ei)
Uterotropic effect
IE50
Log Dmax
Grip score
PB
Change in tumor area
Ka'
Effective molarity
2X PT
Keq
ED80
Cell survival
Volume of ascrit fluid
Bone mineral density
Ataxia
MCC
deltalog10CFU
c.v
Saline control
No. cured/total
Infusion rate
-Log I50
KCS, APP
IE
Dmax
Shift
No. of pos rxns
Protein content
CSF levels
AUC_ratio
Selective toxicity
Antipapilloma activity
TC90
logFu
Duration of block
EC37
-logKa
Tumor area
GOF
Relative PT
Lesion length
Duration of increase in SLA
Life span
LogD6.5
EDP
Ileal activity
Therapeutic dose
MTD/ TGI50
Slope
MTD/2
Accumulation coefficient
36Cl- uptake
LC99
CLT
Absorption
Permeability limited
Survivors at day 9
Delta MST
Plasma Insulin
EF90
Periosteal mineralizing surface
Top1 cleavage activity
Reduction of heart rate
B50
Infected erythrocytes
Shutdown time
Decrease in pressure
Body weight
Relative uterine weight
Intrinsic activity
CC50/EC50
CTE
Onset of action
R/S ratio
Enantiomeric composition
K0.5
Analgesic response
Taste character
Abolition
MPE50
Repolarization time
Mean time to seizure
RBA data
Neutrophils
Susceptibilty Ratio (Liver/Intestine)
pK1
Hemispheres reduction
Urine
Net log change in tumor burden
TVI
Plasma corticosterone
Relative Vmax/Km
Anticonvulsant Activity
Contragestational activity
pK4
pK1d
Therapeutic effect
Inhibition constant
Protected
Clp
Log effect
Induction
OD(540nm)
Hill coefficient
IAr
Normalization
Treated cells
Activity_index
TI50
pKB
Intraperitoneal score
AC50
k x10e3
MIC95
Mean index
MAO deamination
CD50
Epileptogenicity
Max increase in coronary flow
Gastric toxicity
Increase in ear thickness
Transacylation rate
Relative Vmax
Average tumor weight
Log CDGH
In vivo duration
Relative binding affinity
BMD
IZ
IC12
QTc delta
Delta Gm
Cytoprotective effect
K ass app
Regression response
Ka1
Of viability
-Log IC25
Recovery time
p24 synthesis
No. of positive animals
Optimal concentration
Horizontal activity
Kd1
Unreacted drug
ECAUC0.2
Relative phosphorylation
Range of death
CFU/ml
No. of rats displaying DA syndrome
Fraction change
VDR affinity
Parent remaining at time
Verapamil index
Tetramer
APPTT
Rate of phosphorylation
Taq inhibition
NAD+ level
Stroke work
logD
Amax
C12h
Kin
TT
Vascular accumulation ratio
Gastric score
Change of area
IC20
L/CE
Initial average tumor weight
Log10 cfu
GFR
Median survival
pD2 app
Relative effect
Time of half inactivation
Control S/T
No. of survivals
Peak GH
Nucleic acids
Subcut score
RD100
AP50
ER/PR
EMR
Log P'
ALT.
Maximal decrease in IOP
Stimulation
Occupancy
k cat
RRI
HCMV yield reduction
Formation of erythema
Max CF response
Mortality threshold
RatioAUC/MIC
khydr
Highest active dose
Vasopressor activity
Toxicity day survivors
Plasma cholesterol
Control current
Relative inhibition
Perturbations
DA stim
Log 1/EDMES(2.5)
Growth delay
Relative t1/2
fAUC/MIC
CR2
Log K2
CS index
Time to offset
MBIC
P50C
Survival median
TBPS shift
Log sweet/bitter
Paw volume
Free
APD75
K6
Kin x10e3
pEC100
Cell cycle
Max reversing rate
Relative stability
k2/Ki
IC2x
PRCF
TC50
AUC
Vmax rel
Relative amplitude
BW
log10 TCID50
IT100
Rate response
Range of deaths
RT activity
HV interval
Change non HDL-C
Neurotoxicity
KR
Cell growth
Mean day
MBEC
Relative Potency
CLogP
AE activity
Fold_increase
No. of entries
Effect on polyamine pools
Body temp drop
Polyamine
KbS
Max fold increase
Delta TC
Anti-infectious effect
Onset time
TMED50
Increase in dP/dTmax
Speed of performance
AED
CBF Ratio
Animals with palpable tumor
Ccontrol
MIC50
Removal
IOP lowering
Mortality number
Affinity state 1
Protonated
Cholesterol Concentration
BSR
K H
Topical dosage
Activity ratio
% dose
Offset time
Rf
BP decrease
mequiv of HCl
Average bile flow
P50
ABC
Rate constant (k)
HDL-C change
ND50
Average
Relative cytotoxicity
Log Pn
RIS
Surviving fraction
Glutathione
Mean maximumtemp drop
TPO
Potency vs EKC
Thyroid status
Log geometric mean
SC200
Flea
KT4
Na
Selectivity ratio S3/2
Content of cell cycle
IC50/[E]
Convulsion threshold
Total no. of turns
Kd2
Virus yield reduction
No. of shocks accepted/5 min
Max tolerated dose
Antitumour activity
MD
Ca2+ serum
Metabolic turnover
PCA
Mean day of death for total dead
k3/ki
Retches
ID75
CC
Change in IC50
BMF
Eff
MDA content
Behavioral observation
Expression
Diameter
Total lysis
PFC
Increase in life-span
Immobility time
LH
Mean decrease
Change of predose
T50
pKa_decrease
Max score
C20 FRP
Relative activity of AChE
Na+ excretion
hSlo current
Delta ERPc
K cat/Kinact
Ks/i
Log IC50
sigmaSH
Change TC
Histamine release
ED15
Change in systolic BP
Immobility
Residue fraction
Adverse effect
T-C
Fabs
ft1/2
APD90
Modulation factor
Survival ratio
RC50
K HOX
Clined screen test
Body temperature
HTD
pD'2
Max stimulation
Log Pion
Pregnancy index
2x TG
Log kill
EF200
Median survival day
Uncut DNA
NOL
Palpha
Body weight loss at nadir
Average inhibition
Log2 MIC
Astrocyte reversal
Log 1/LD50 (mM kg-1)
CT10 ratio
Spleen weight
Activity MABP
ED250
Thymus weight change
Cholesterol content
Tritium release
Tumor inhibition
logSI
Reduction of live worms
Q1/2
Ulcerative index
DNA
Delta coronary flow
LogD5.5
Transacetylation rate
Oligo modified
Average tumor volume
deltaT
RVR ED15
Average ratio
GI25
Lowest effective concentration
Delta latency time
Excretion K+
Response value
KiAH
STY seizure
ED delta5
No. of tumors/mouse
Cl - current change
Uterine wet weight
Max aggregation response
ASAT levels
Skin scaling
Acetylcholine release
Competition factor
GAG
BGL
pBBB
Optimum T/C
Capacity
Distribution (dose/g)
C5 min
Consumption
Loss
Residual RR activity
AUC glu
Total cholesterol
Peroxidase rate
Kiuc
AI recovery time
Cell cycle analysis
FPG correction
Relative velocity
Recovered in bile
3D PSA
MRP
Latency to step through
Degradation ratio
IM
Ratio ED50
Mean IC70
ED60
Inhibition index
Net log cell kill
logPi
Incidence
Log CDQR
Log SP
MGC
kaKr/kr
k0
-Log Kb
log KOA
RTW
MPE
Muscarinic agonist index
Therapeutic ratio
Uptake selectivity
GI clearence
GH
ED50
Average change in weight
Molar content
pMax
Ki
K12
C10 air
Max cAMP
IN
NG ratio
BEI
Amount of TNF-alpha
HDL-C
Delta P50
ERH
EC10x
NC
Dissociation rate constant
Hypocotyl length
Relative peroxidation
Excretion Cl-
COI
Max T/C
Rate of formation
Generalization
pEC50
ED10
MEC50
VLDL
PCoct
Peak striatal uptake
Inhibition over time
[EA]
ODC activity
Survival days
Time constant T3
U osm
Creatinine_CL
No. of protected/tested
Inhibitory activity ratio
NI
Formaldehyde
Delta MABP
Temperature change
ILS (T/C)
log K
Log BB
Increase in blood pressure
Inhibitory index
Increased
KDs
Log 1/ED40
Group toxicity
Inhibitory zone
k2''
ISA
Ki' uncomp
Remaining at 40 min
K obs / s
PI
Control tumor volume
kon
Food
Max BSR
Anticonvulsant dose
M-agonist index
Kp
D2 selectivity
Time of peak action
Foci/dish
PHA
MDR ratio
TGI correlation coefficient
Tlast
MFI
No. of pits/slice
MDD
OD
Observed relaxivity
Lactone production
Compound in urine
Kel
Activit y
logD7.5
Observed log APA
TLm
tRNA peak exclusion
Etopic beats
Distribution coefficient
Ratio of stimulation
cAMP activity index
Ratio (Ci/Ce)
Cytostatic concentration
TD50/ED50
Blood level
DNA photo-crosslinking
Tumors with CR
Kcat/Km
Range of survival
C2
pGC50
Erythema formation
CT10
Supressive effect
K eff
LD50 x 1/20
Smax
Fe removed
ACAT activity
Hx shift
Microsomal stability
Cl-
Release
FE
Diuresis
Log GTI
Absorbance
Zone reduction
pKa value
Antiviral index
Min effective dose
Ratio of distribution
Palmitoyl-CoA oxid
Antiviral activity
I16
PTD50
VERP
Cmax/Tmax
Log [-7]
R+V
Log [-8]
Locomotion
EII50
Cell protein
Change of weight
Feces
Cytocidal effect
TCID50
Parasite_Clearance_time
FRP
CD90
Average GI50
pKb
ko
ED50 mg/kg
I/M ratio
Relative rate
Kh
Rate of rotation
Pleural volume
Accumulated counts/30
Ip score
IC50L
C24
Log Ko/w
No. of mice receovered
Cl
-Log 1/Kb
MTD ratio
KiA
Kaliuretic activity
MF
GD200 [d]
Day 22-T/C
Delta mV
Discrimination ratio
Net grain counts
Anticancer activity
KiL
Arrhythmia score
Biodistribution ratio
Change from Control (LV dp/dt)
Macrophage activation
Retraction time
DA utilization
Max. activation
Sigmap
C10 air/C10 N2
BNa
max Delta Vmax
Carbamoylating activity
%R
Oral duration
Dose
Oncostatic index
Efficiency
Critical concentration
Cytotoxicity
deltalog10CFU/ml
Days to tumor doubling
Initial activity
Fold induction
DNA single strand breaks
Change in blood glucose
Ka
Disease control
Scavenging activity
pNF
Reduction in respiratory volume
MCHC
Subcutaneous score
Retention ratio
Synergy with methicillin
Glucose lowering ob/ob dose
Control DMSO Pyknosed Nuclei (%)
Control DMSO Mitotic Cells (%)
Control DMSO Tubulin Phenotype Different Cells (%)
Control DMSO Mitochondria Different-Phenotype Cells (%)
Control DMSO Membrane Permeable-Phenotype Cells (%)
Population Hoechst High Intensity Objects (%)
Population Normal (%)
Population Apoptotic (%)
Population Healthy Nuclei (%)
Population Fragmented Nuclei (%)
Population Pyknosed Nuclei (%)
Population Mitotic Cells (%)
Population Tubulin-Different-Phenotype (%)
Population Mitochondria Different-Phenotype (%)
Population Membrane Permeable-Phenotype (%)
Control DMSO Total Cells
Control DMSO Healthy Nuclei (%)
Total Cell Count
Control DMSO Fragmented Nuclei %
Control DMSO Pyknosed Nuclei (%)
LUCIFERASE EXPRESSION CONTROL - IC50
Tissue Severity Score
Percent Effect
% Ctrl
% Cell Death
Repellency
Z score
LUCIFERASE INFECTION ASSAY - IC90
Thermal melting change
ALBGLOB
HepSE_bilirubinemia
INHIBITION
GGT Increase - Activity Score
Hepatotoxicity (granulomatous hepatitis)
BASO
CK
mortality
Growth Rate
% Control
Drug metabolism
Delta TM
LUCIFERASE INFECTION ASSAY - IC50
LYMLE
SODIUM
LIPASE
HEPG2TOX ASSAY - CC90
Residual Activity
Biotransformation
BILDIR
GLUC
%Inhib (Mean)
PHOSLPD
%Max (Mean)
NEUTLE
LYM
ALP
BASOLE
PHOS
MIC=>90
AbsAC1000_uM
AbsAC40_uM
MONO
log2FC
HEPG2TOX ASSAY - CC50
LUCIFERASE EXPRESSION CONTROL - IC90
PROT
HCT
Hepatotoxicity (mechanism)
BILI
POTASSIUM
CREAT
AST
TRIG
Hepatotoxicity (association with vascular disease)
Hepatotoxicity
CALCIUM
SGPT Increase - Number of Reports
Control DMSO Apoptotic Cells (%)
Hepatotoxicity (time to onset)
log(activity)
Compound recovery
Drug degradation
FIBRINO
pXC50
Drug recovery
MCH
Phytotoxicity
CHOL
CHLORIDE
delta Tm Staurosporine positive control
GGT Increase - Index Value
PLAT
MIC=>95
HGB
CO2
Control DMSO Growth Rate
HepSE_cholecystitis
GGT
MIC>99
pA2(app)
MBC99.9
ALB
FPD measurement
Drug uptake(free)
EOS
Therm_solubility
HepSE_jaundice
PXC50
HepSE_elevated liver function tests
GGT Increase - Number of Reports
pKa_A1
URATE
AFC50
D40
AbsAC50_uM
MCV
RBCNUC
log(RatioIC50)
IC15
Hepatotoxicity (successful reintroduction)
NEUTSG
HepSE_liver fatty
AbsAC26_uM
MFC<=99.9
Blood/Plasma ratio
RETIRBC
LDH Increase - Number of Reports
K(p,uu,brain)
MOTILITY REDUCTION/CYTOTOXICITY
Conc @ Max Fold Incr
TERMBW
Hepatotoxicity (moderate)
AC40
EOSLE
SGOT Increase - Activity Score
Composite Activity - Marginal
R50
MBIC50
Hepatotoxicity (chronic liver disease)
HepSE_cholelithiasis
MONOLE
Mean % growth (n = 2) for 10.0 µM probe concentration
Drugexcretion
HepSE_Combined Scores
Max_Activity
log(1/ED50)
LDH Increase - Index Value
Hepatotoxicity (benign tumour)
GR80
GI80
GI90
Schizont size
DILI_severity_class
Cell Proliferation EC50
IC50 relative
% residual kinase activity
log(ratio)
MHC10
TOP
MBIC90
log(%)
delta Tm
MIC>90
DILI_Concern
HC10
AFI
Relative Growth
Hepatotoxicity (acute)
log(1/LD50)
Ke(app)
Normalized abundances for DMSO
MRTlast
alphaKi
MED=>50
Hepatotoxicity (animal toxicity known)
SGPT Increase - Activity Score
AbsAC35_uM
DNAUC
AbsAC35
MRT(t)
Hepatotoxicity (choleostasis)
Hepatotoxicity (cirrhosis)
Drug excretion
HepSE_cirrhosis
Hit score
Hepatotoxicity (cytolytic)
Potency_Dyrk1b_uM
log(43000/Ki)
Occ
% of inhibition
Concentration @ Maxi
log10(%HIA +10)
log(1/BC)
% inhibition
MBC99.5
Retention_time
MFC99.5
AUClast
Alkaline Phosphatase Increase - Number of Reports
log(ILSmax)
In vitro activity
log(1/MIC)
% Residual activity with Skepinone-L
BOTTOM
Kinetic_solubility
log(RBA)
LC80
log(1/I50)